Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells
- Authors:
- Xin Zhang
- Hesheng Luo
-
Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China - Published online on: December 19, 2017 https://doi.org/10.3892/ol.2017.7645
- Pages: 3313-3320
This article is mentioned in:
Abstract
International Agency for Research on Cancer, . Colorectal cancer estimated incidence, mortality and prevalence worldwide in 2012 [EB/OL]. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx | |
Zong-Guang Zhou, Lie Yang, Yuan Li, et al: The 30 years' changes of colorectal cancer and the strategies in China. Chin J Practic Surg. 32:693–696. 2012.(In Chinese). | |
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI | |
Wieck MM, Spurrier RG, Levin DE, Mojica SG, Hiatt MJ, Reddy R, Hou X, Navarro S, Lee J, Lundin A, et al: Sequestration of vascular endothelial growth factor (VEGF) induces late restrictive lung disease. PLoS One. 11:e01483232016. View Article : Google Scholar : PubMed/NCBI | |
Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG and Ma T: Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol. 9:974–977. 2003. View Article : Google Scholar : PubMed/NCBI | |
Willems-Widyastuti A, Vanaudenaerde BM, Vos R, Dilisen E, Verleden SE, De Vleeschauwer SI, Vaneylen A, Mooi WJ, de Boer WI, Sharma HS and Verleden GM: Azithromycin attenuates fibroblast growth induced vascular endothelial growth factor via p38(MAPK)signaling in human airway smooth muscle cells. Cell Biochem Biophys. 67:331–339. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zachary I and Gliki G: Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiov Asc Res. 49:568–581. 2001. View Article : Google Scholar | |
Zeng H, Sanyal S and Mukhopadhyay D: Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. Biol Chem. 276:32714–32719. 2001. View Article : Google Scholar | |
Xu XL, Ling ZQ, Chen W, Xu YP and Mao WM: The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: A meta-analysis. Cancer Biomark. 13:105–113. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Liu X, Zhang J, Li L and Liu C: The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer. Oncol Lett. 4:763–766. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ratcliffe PJ: HIF-l and HIF-2: Working alone or together in hypoxia? J Clin Invest. 117:862–865. 2007. View Article : Google Scholar : PubMed/NCBI | |
Li W, Xiong ZW, Li HW, Hu HX, Zhang P, Su H, Huang Y, Zhang HD and Xun FH: Expression of COX-2, VEGF and E -cad in breast cancer and their clinicopathologic significance. Chin J Curr Adv Gen Surg. 13:766–771. 2010.(In Chinese). | |
Zhang P, Dong L, Yan K, Long H, Yang TT, Dong MQ, Zhou Y, Fan QY and Ma BA: CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF. Oncol Rep. 30:1753–1761. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L and Zhang Y: Clinicopathologic significance of HIF-1α, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol. 2010:pii:5375312010. View Article : Google Scholar | |
Ahluwalia A and Tarnawski AS: Critical role of hypoxia sensor-HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem. 19:90–97. 2012. View Article : Google Scholar : PubMed/NCBI | |
De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A and Maggiolini M: HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer-associated fibroblasts (CAFs). Breast Cancer Res. 15:R642013. View Article : Google Scholar : PubMed/NCBI | |
Decourt B, Drumm-Gurnee D, Wilson J, Jacobson S, Belden C, Sirrel S, Ahmadi M, Shill H, Powell J, Walker A, et al: Poor safety and Tolerability Hamper Reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer's disease: Results from a Double-Blind Placebo-Controlled trail. Curr Alzheimer Res. 14:403–411. 2017. View Article : Google Scholar : PubMed/NCBI | |
Raturi R, Patel AA and Carter JD: Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis. Clin Rheumatol. 36:725–728. 2017. View Article : Google Scholar : PubMed/NCBI | |
Anargyrou K, Dimopoulos MA, Sezer O and Terpos E: Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma. 49:677–689. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bombini G, Canetti C, Rocha FA and Cunha FQ: Tumour necrosis factor-alpha mediates neutrophil migration to the knee synovial cavity during immune inflammation. Eur J Pharmacol. 496:197–204. 2004. View Article : Google Scholar : PubMed/NCBI | |
Deng L, Ding W and Granstein RD: Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol. 121:1060–1065. 2003. View Article : Google Scholar : PubMed/NCBI | |
Keifer JA, Guttridge DC, Ashburner BP and Baldwin AS Jr: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 276:22382–22387. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yu J, Liu F, Sun Z, Sun M and Sun S: The enhancement of radiosensitivity in human esophageal carcinoma cell by thalidomide and its potential mechanism. Cancer Biother Radiopharm. 26:219–227. 2011. View Article : Google Scholar : PubMed/NCBI | |
Pan J, Lu GP and Yu ZJ: Thalidomide on anti-tumor research. Chin J Cancer Prev Treat. 19:552–555. 2012. | |
Uach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ and Prince HM: Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 24:22–32. 2010. View Article : Google Scholar : PubMed/NCBI | |
Girgis E, Mahoney J, Darling-Reed S and Soliman M: Arsenic trioxde enhance the cytotoxic effect of thalidomide in a KG-la human acute mylogenous leukemia cell line. Oncol Lett. 1:473–479. 2010. View Article : Google Scholar : PubMed/NCBI | |
Xu X, Xiong G, Li E, Zhu H, Lio H, Shen G and Wu S: Effect of thalidomide on cytodynamics and VEGF expression of human pancreatic cancer cells. Chin J Gastroenterol. 9:511–513. 2012. | |
Gao S, Yang XJ, Zhang WG, Ji YW and Pan Q: Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl). 122:1260–1266. 2009.PubMed/NCBI | |
Lin YC, Shun CT, Wu MS and Chen CC: A novel anticancer effect of thalidomide: Inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res. 12:7165–7173. 2006. View Article : Google Scholar : PubMed/NCBI | |
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI | |
Dahan L, Sadok A, Formento JL, Seitz JF and Kovacic H: Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 158:610–620. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lv J, Liu N, Liu KW, Ding AP, Wang H and Qiu WS: A Randomised controlled phase II trial of the combination of XELOX with thalidomide for the first-line treatment of metastatic colorectal cancer. Cancer Biol Med. 9:111–114. 2012.PubMed/NCBI | |
Govindarajan R: Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston park). 16(4 Suppl 3): S23–S26. 2002. | |
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI | |
Zhang MM, Cai L and LA DD: Study on mechanism of thalidomide in human ovarian cancer cells SKOV3 in vitro. J Practi Med. 26:2693–2696. 2010. | |
Huang YT, Cheng CC, Chiu TH and Lai PC: Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. Int J Oncol. 47:1711–1724. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang C and Youle RJ: The role of mitochondria in apoptosis*. Annu Rev Genet. 43:95–118. 2009. View Article : Google Scholar : PubMed/NCBI | |
Gu W, Zhao XG and Zhang X: Formononetin induce apoptosis of SKOV3 cells through regulating the expression of Bax and Bcl-2. Sichuan J Physiol. 36:60–62. 2014. | |
Qiao Z, Yuan J, Shen J, Wang C, He Z, Hu Y, Zhang M and Xu C: Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo. Oncol Lett. 9:2353–2360. 2015. View Article : Google Scholar : PubMed/NCBI | |
Marriott JB, Clarke LA, Czajks A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI and Dalgleish AG: A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res. 63:593–599. 2003.PubMed/NCBI | |
Meller S and Bhandari V: VEGF levels in humans and animal models with RDS and BPD: Temporal relationships. Exp Lung Res. 38:192–203. 2012. View Article : Google Scholar : PubMed/NCBI | |
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z and Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 5:623–628. 1999. View Article : Google Scholar : PubMed/NCBI | |
Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM and Elias JA: Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 10:1095–1103. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhao T, Zhao W, Meng W, Liu C, Chen Y, Gerling IC, Weber KT, Bhattacharya SK, Kumar R and Sun Y: VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infracted myocardium. Am J Transl Res. 7:697–709. 2015.PubMed/NCBI | |
Iacovelli R, Sternberg CN, Porta C, Verzoni E, de Braud F, Escudier B and Procopio G: Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: A systematic review and meta-analysis. Curr Drug Targets. 16:164–170. 2015. View Article : Google Scholar : PubMed/NCBI | |
Quittet MS, Touzani O, Sindji L, Cayon J, Fillesoye F, Toutain J, Divoux D, Marteau L, Lecocq M, Roussel S, et al: Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat. Acta Biomater. 15:77–88. 2015. View Article : Google Scholar : PubMed/NCBI | |
Dzietko M, Derugin N, Wendland MF, Vexler ZS and Ferriero DM: Delayed VEGF treatment enhances angiogenesis and recovery after neonatal focal rodent stroke. Transl Stroke Res. 4:189–200. 2013. View Article : Google Scholar : PubMed/NCBI | |
Yang X, Zhu H, Ge Y, Liu J, Cai J, Qin Q, Zhan L, Zhang C, Xu L, Liu Z, et al: Melittin enhances radiosensitivity of hypoxic head and neck squamous cell carcinoma by suppressing HIF-1α. Tumour Biol. 35:10443–10448. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wilkinson-Berka JL: Vasoactive factors and diabetic retinopathy: Vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des. 10:3331–3348. 2004. View Article : Google Scholar : PubMed/NCBI | |
Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, et al: Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis. Leuk Res. 38:756–763. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tan H, Chen H, Xu C, Ge Z, Gao Y, Fang J, Liu W and Xiao S: Role of vascular endothelial growth factor in angiodysplasia: An interventional study with thalidomide. J Gastroenterol Hepatol. 27:1094–1101. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hernandez Mde O, Fulco Tde O, Pinheiro RO, Pereira Rde M, Redner P, Sarno EN, Lopes UG and Sampaio EP: Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway and lower cytokine response. Eur J Pharmacol. 670:272–279. 2011. View Article : Google Scholar : PubMed/NCBI | |
Abcouwer SF: Angiogenic factors and cytokines in diabetic retinopathy. J Clin Cell Immunol. (Suppl 1)2013.PubMed/NCBI | |
Huang YF, Yang CH, Huang CC, Tai MH and Hsu KS: Pharmacological and genetic accumulation of hypoxia-inducible factor-1alpha enhances excitatory synaptic transmission in hippocampal neurons through the production of vascular endothelial growth factor. J Neurosci. 30:6080–6093. 2010. View Article : Google Scholar : PubMed/NCBI | |
Carbajo-Pescador S, Ordonez R, Benet M, Jover R, García-Palomo A, Mauriz JL and González-Gallego J: Inhibition of VEGF expression through blockade of Hif1α and STAT3 signaling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 109:83–91. 2013. View Article : Google Scholar : PubMed/NCBI | |
Nechemia-Arbely Y, Khamaisi M, Rosenberger C, Koesters R, Shina A, Geva C, Shriki A, Klaus S, Rosen S, Rose-John S, et al: In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin Exp Pharmacol Physiol. 40:262–272. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dourlat J, Liu WQ, Sancier F, Edmonds T, Pamonsinlapatham P, Cruzalegui F and Garbay C: A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity. Biochimie. 91:996–1002. 2009. View Article : Google Scholar : PubMed/NCBI | |
Majumder S, Sreedhara SR, Banerjee S and Chatterjee S: TNF-α signaling beholds thalidomide saga: A review of mechanistic role of TNF-α signaling under thalidomide. Curr Top Med Chem. 12:1456–1467. 2012. View Article : Google Scholar : PubMed/NCBI | |
El-Aarag BY, Kasai T, Zahran MA, Zakhary NI, Shigehiro T, Sekhar SC, Agwa HS, Mizutani A, Murakami H, Kakuta H and Seno M: In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs. Int Immunopharmacol. 21:283–292. 2014. View Article : Google Scholar : PubMed/NCBI | |
Cook KM and Figg WD: Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI | |
People's Republic of China national health and Family Planning Commission of medical affairs authority, Tumor branch of Chinese Medical Association, . Standard for diagnosis and treatment of colorectal cancer (2015). Chin J Practi Surg. 35:1177–1191. 2015. | |
Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI | |
Voland C, Bord A, Péleraux A, Pénarier G, Carrière D, Galiègue S, Cvitkovic E, Jbilo O and Casellas P: Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther. 5:2149–2157. 2006. View Article : Google Scholar : PubMed/NCBI | |
Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, et al: FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: A propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol. 27:843–849. 2016. View Article : Google Scholar : PubMed/NCBI | |
Murphy S, Davey RA, Gu XQ, Haywood MC, McCann LA, Mather LE and Boyle FM: Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. J Neuroancol. 85:181–189. 2007. View Article : Google Scholar | |
Mihara M, Hashizume M, Yoshida H, Suzuki M and Shiina M: IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 122:143–159. 2012. View Article : Google Scholar : PubMed/NCBI | |
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 334:297–314. 1998. View Article : Google Scholar : PubMed/NCBI | |
Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C, Quesenberry PJ, Resnick MB and Chatterjee D: RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer. 13:4632013. View Article : Google Scholar : PubMed/NCBI |